CORVERT

What it isClass III hERG potassium-channel blocker; acute conversion of atrial flutter and fibrillation.
Why this oneIt converts atrial flutter more reliably than atrial fibrillation and acts rapidly by infusion.
What limits itPotentially fatal torsades requires continuous ECG observation after dosing with magnesium and resuscitation capability available.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Atrial fibrillation/flutter (conversion to sinus rhythm) | ≥60 kg | 1 mg (one vial) IV over 10 min | 1 mg IV over 10 min | |
| Atrial fibrillation/flutter | <60 kg | 0.01 mg/kg (0.1 mL/kg) IV over 10 min | 0.01 mg/kg IV over 10 min |
Renal Undefined
Hepatic Undefined
May repeat same dose once, 10 min after completion of first infusion, if arrhythmia persists
Available strengths
Pregnancy Teratogenic and embryocidal in rats; give only if benefit outweighs fetal risk
Lactation Undefined
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 0.1 mg/mL | inj | per unit | not offered |
⚠ BOXED WARNING
Defining liabilityAcute torsades and other life-threatening ventricular arrhythmias